Bibliografías temáticas / Oxaliplatin / Artículos de revistas
Siga este enlace para ver otros tipos de publicaciones sobre el tema: Oxaliplatin.

Artículos de revistas sobre el tema "Oxaliplatin"

Autor: Grafiati
Publicado: 4 de junio de 2021
Última modificación: 25 de julio de 2025

Crea una cita precisa en los estilos APA, MLA, Chicago, Harvard y otros

Elija tipo de fuente:

Consulte los 50 mejores artículos de revistas para su investigación sobre el tema "Oxaliplatin".

Junto a cada fuente en la lista de referencias hay un botón "Agregar a la bibliografía". Pulsa este botón, y generaremos automáticamente la referencia bibliográfica para la obra elegida en el estilo de cita que necesites: APA, MLA, Harvard, Vancouver, Chicago, etc.

También puede descargar el texto completo de la publicación académica en formato pdf y leer en línea su resumen siempre que esté disponible en los metadatos.

Explore artículos de revistas sobre una amplia variedad de disciplinas y organice su bibliografía correctamente.

1

Ye, Tong, Chen Wu, Jintong Na, Xiyu Liu, and Yong Huang. "Multi-Pathway Study for Oxaliplatin Resistance Reduction." Current Issues in Molecular Biology 47, no. 3 (2025): 172. https://doi.org/10.3390/cimb47030172.

Texto completo
Resumen
Chemotherapy for cancer frequently uses platinum-based medications, including oxaliplatin, carboplatin, and cisplatin; however, due to their high systemic toxicity, lack of selectivity, drug resistance, and other side effects, platinum-based medications have very limited clinical application. As a first-line medication in antitumor therapy, oxaliplatin must be administered to minimize side effects while achieving anticancer objectives. A new CDC7 inhibitor called XL413 has demonstrated promising antitumor therapeutic effects in a variety of malignant tumors and may have anticancer properties.
Los estilos APA, Harvard, Vancouver, ISO, etc.
2

Ain, Noor ul, Nusrat Bano, Anwar Ejaz Beg, Kamran Hameed, Talha Bin Fayyaz, and Rafia Sadaf. "HEMATOLOGICAL TOXICITY IN RATS;." Professional Medical Journal 24, no. 02 (2017): 342–46. http://dx.doi.org/10.29309/tpmj/2017.24.02.525.

Texto completo
Resumen
Objectives: Oxaliplatin causes hematological toxicities in clinical setting whichlimits its efficacy. The aim of this study is to investigate the therapeutic effects of Andrographispaniculata against hematological toxicity caused by oxaliplatin. Study design: Experimentalanimal study. Period: Study takes 8 month from March 2015 to Oct 2015. Setting: Dow universityanimal house. Method: Wistar albino male rats, divided into 3 equals groups (n=6): GroupN* was a control group (0.9% normal saline), Group NP0 was Oxaliplatin treated group andGroup NP1 was prophylactically treated with Andrographis p
Los estilos APA, Harvard, Vancouver, ISO, etc.
3

Grothey, A., D. A. Nikcevich, J. A. Sloan, et al. "Evaluation of the effect of intravenous calcium and magnesium (CaMg) on chronic and acute neurotoxicity associated with oxaliplatin: Results from a placebo-controlled phase III trial." Journal of Clinical Oncology 27, no. 15_suppl (2009): 4025. http://dx.doi.org/10.1200/jco.2009.27.15_suppl.4025.

Texto completo
Resumen
4025 Background: Cumulative sNT is the dose-limiting toxicity of oxaliplatin which commonly leads to early discontinuation of oxaliplatin-based therapy in the palliative and adjuvant setting. We recently demonstrated the protective effect of CaMg against oxaliplatin-induced sNT as assessed by NCI-CTC (Nikcevich ASCO 2008). It is unclear, though, if CaMg reduced acute and/or chronic, cumulative sNT. Methods: 104 pts with colon cancer undergoing adjuvant therapy with FOLFOX were randomized to IV CaMg (1g calcium gluconate plus 1g magnesium sulfate pre- and post-oxaliplatin) or placebo (PL) in a
Los estilos APA, Harvard, Vancouver, ISO, etc.
4

Pires, Lívia Márcia Vidal, and Patrícia Dos Santos Claro Fuly. "Mapeamento de fatores clínicos preditivos da neuropatia sensorial periférica induzida por oxaliplatina: revisão sistemática." Revista Recien - Revista Científica de Enfermagem 11, no. 35 (2021): 382–97. http://dx.doi.org/10.24276/rrecien2021.11.35.382-397.

Texto completo
Resumen
O objetivo deste estudo foi realizar um mapeamento dos fatores clínicos preditivos da Neuropatia Sensorial Periférica induzida pela Oxaliplatina. Para tanto, foi realizada uma revisão sistemática, elaborada a partir das recomendações da diretriz PRISMA. A estratégia PICO também foi utilizada para formular a questão de pesquisa e orientar a busca nas bases de dados: PubMed, Embase, Scopus, BVS/IBECS e CINAHL. Foram selecionadas 26 publicações para análise final e inclusão na revisão. As publicações foram classificadas quanto ao nível de evidência e grau de recomendação, de acordo com o sistema
Los estilos APA, Harvard, Vancouver, ISO, etc.
5

Cho, Soohee, Kristen Miller, Jacqueline Rowley, et al. "OTHR-03. Oxaliplatin as a hearing-sparing alternative to carboplatin in tandem autologous stem cell transplants in pediatric CNS malignancy." Neuro-Oncology 24, Supplement_1 (2022): i147. http://dx.doi.org/10.1093/neuonc/noac079.542.

Texto completo
Resumen
Abstract BACKGROUND: Intensive chemotherapy with tandem autologous stem cell transplants (autoSCT) is shown to improve survival for children with CNS malignancy. Platinum-based chemotherapeutic agents in these regimens, mainly cisplatin and carboplatin, have resulted in significant sensorineural hearing loss. Oxaliplatin, a newer platinum-based agent, is considered less ototoxic. Empiric substitution of oxaliplatin for carboplatin in preparative regimens for autoSCT have been tried. However, the survival and ototoxicity outcomes have not been studied. OBJECTIVE: To compare the overall survival
Los estilos APA, Harvard, Vancouver, ISO, etc.
6

Connors, Jeremy S., Linda Zhang, Koji Sasaki, et al. "Protective Role of Oxaliplatin Among Platinum-Based Therapies in the Development of Therapy-Related Myeloid Neoplasms." Blood 142, Supplement 1 (2023): 4220. http://dx.doi.org/10.1182/blood-2023-190672.

Texto completo
Resumen
Introduction As a DNA-damaging agent, platinum-based chemotherapy serves as a cornerstone in cancer treatment. However, its widespread use has been associated with increased incidence of therapy-related myeloid neoplasms (t-MNs). Among the three most commonly used platinum chemotherapies - cisplatin, carboplatin, and oxaliplain - oxaliplatin presents a distinctive clinical usage and toxicity profile. Predominantly utilized in treating gastrointestinal tract (GI) cancers, oxaliplatin manifests a distinct toxicity pattern when compared to its counterparts. This variance is supported by a previou
Los estilos APA, Harvard, Vancouver, ISO, etc.
7

Lipp and Hartmann. "Platinverbindungen: Metabolismus, Toxizität und supportive Strategien." Praxis 94, no. 6 (2005): 187–98. http://dx.doi.org/10.1024/0369-8394.94.6.187.

Texto completo
Resumen
Mit Oxaliplatin wurde der erste Vertreter der DACH-Platin-Verbindungen in die Klinik eingeführt (DACH: Diaminocyclohexan), der bei guter Verträglichkeit die höchste Aktivität zur Behandlung des fortgeschrittenen kolorektalen Karzinoms aufweist. Aufgrund der hohen, gegenüber Cisplatin besseren in vitro-Aktivität des Oxaliplatins auch gegenüber anderen Tumorentitäten sind die klinischen Studien mit Oxaliplatin in den letzten Jahren erheblich ausgeweitet worden. Der breite Einsatz der genannten Platinverbindungen darf allerdings nicht darüber hinwegtäuschen, dass diese Wirkstoffe über beachtliche
Los estilos APA, Harvard, Vancouver, ISO, etc.
8

&NA;. "Oxaliplatin." Reactions Weekly &NA;, no. 1378 (2011): 27. http://dx.doi.org/10.2165/00128415-201113780-00098.

Texto completo
Los estilos APA, Harvard, Vancouver, ISO, etc.
9

&NA;. "Oxaliplatin." Reactions Weekly &NA;, no. 1384 (2012): 43. http://dx.doi.org/10.2165/00128415-201213840-00174.

Texto completo
Los estilos APA, Harvard, Vancouver, ISO, etc.
10

&NA;. "Oxaliplatin." Reactions Weekly &NA;, no. 1385 (2012): 35. http://dx.doi.org/10.2165/00128415-201213850-00129.

Texto completo
Los estilos APA, Harvard, Vancouver, ISO, etc.
11

&NA;. "Oxaliplatin." Reactions Weekly &NA;, no. 1388 (2012): 24. http://dx.doi.org/10.2165/00128415-201213880-00093.

Texto completo
Los estilos APA, Harvard, Vancouver, ISO, etc.
12

&NA;. "Oxaliplatin." Reactions Weekly &NA;, no. 1389 (2012): 34. http://dx.doi.org/10.2165/00128415-201213890-00124.

Texto completo
Los estilos APA, Harvard, Vancouver, ISO, etc.
13

&NA;. "Oxaliplatin." Reactions Weekly &NA;, no. 1390 (2012): 28–29. http://dx.doi.org/10.2165/00128415-201213900-00109.

Texto completo
Los estilos APA, Harvard, Vancouver, ISO, etc.
14

&NA;. "Oxaliplatin." Reactions Weekly &NA;, no. 1390 (2012): 29. http://dx.doi.org/10.2165/00128415-201213900-00112.

Texto completo
Los estilos APA, Harvard, Vancouver, ISO, etc.
15

&NA;. "Oxaliplatin." Reactions Weekly &NA;, no. 1391 (2012): 32. http://dx.doi.org/10.2165/00128415-201213910-00119.

Texto completo
Los estilos APA, Harvard, Vancouver, ISO, etc.
16

&NA;. "Oxaliplatin." Reactions Weekly &NA;, no. 714 (1998): 12. http://dx.doi.org/10.2165/00128415-199807140-00042.

Texto completo
Los estilos APA, Harvard, Vancouver, ISO, etc.
17

&NA;. "Oxaliplatin." Reactions Weekly &NA;, no. 1161 (2007): 20. http://dx.doi.org/10.2165/00128415-200711610-00064.

Texto completo
Los estilos APA, Harvard, Vancouver, ISO, etc.
18

&NA;. "Oxaliplatin." Reactions Weekly &NA;, no. 1166 (2007): 19. http://dx.doi.org/10.2165/00128415-200711660-00058.

Texto completo
Los estilos APA, Harvard, Vancouver, ISO, etc.
19

&NA;. "Oxaliplatin." Reactions Weekly &NA;, no. 1174 (2007): 21–22. http://dx.doi.org/10.2165/00128415-200711740-00062.

Texto completo
Los estilos APA, Harvard, Vancouver, ISO, etc.
20

&NA;. "Oxaliplatin." Reactions Weekly &NA;, no. 1180 (2007): 32. http://dx.doi.org/10.2165/00128415-200711800-00099.

Texto completo
Los estilos APA, Harvard, Vancouver, ISO, etc.
21

&NA;. "Oxaliplatin." Reactions Weekly &NA;, no. 1187 (2008): 21. http://dx.doi.org/10.2165/00128415-200811870-00068.

Texto completo
Los estilos APA, Harvard, Vancouver, ISO, etc.
22

&NA;. "Oxaliplatin." Reactions Weekly &NA;, no. 1188 (2008): 18–19. http://dx.doi.org/10.2165/00128415-200811880-00060.

Texto completo
Los estilos APA, Harvard, Vancouver, ISO, etc.
23

&NA;. "Oxaliplatin." Reactions Weekly &NA;, no. 1189 (2008): 27–28. http://dx.doi.org/10.2165/00128415-200811890-00086.

Texto completo
Los estilos APA, Harvard, Vancouver, ISO, etc.
24

&NA;. "Oxaliplatin." Reactions Weekly &NA;, no. 1191 (2008): 20. http://dx.doi.org/10.2165/00128415-200811910-00063.

Texto completo
Los estilos APA, Harvard, Vancouver, ISO, etc.
25

&NA;. "Oxaliplatin." Reactions Weekly &NA;, no. 1192 (2008): 27. http://dx.doi.org/10.2165/00128415-200811920-00072.

Texto completo
Los estilos APA, Harvard, Vancouver, ISO, etc.
26

&NA;. "Oxaliplatin." Reactions Weekly &NA;, no. 1194-1195 (2008): 28. http://dx.doi.org/10.2165/00128415-200811940-00102.

Texto completo
Los estilos APA, Harvard, Vancouver, ISO, etc.
27

&NA;. "Oxaliplatin." Reactions Weekly &NA;, no. 1123 (2006): 15. http://dx.doi.org/10.2165/00128415-200611230-00045.

Texto completo
Los estilos APA, Harvard, Vancouver, ISO, etc.
28

&NA;. "Oxaliplatin." Reactions Weekly &NA;, no. 1128 (2006): 15. http://dx.doi.org/10.2165/00128415-200611280-00048.

Texto completo
Los estilos APA, Harvard, Vancouver, ISO, etc.
29

&NA;. "Oxaliplatin." Reactions Weekly &NA;, no. 1129 (2006): 16. http://dx.doi.org/10.2165/00128415-200611290-00055.

Texto completo
Los estilos APA, Harvard, Vancouver, ISO, etc.
30

&NA;. "Oxaliplatin." Reactions Weekly &NA;, no. 1138 (2007): 21–22. http://dx.doi.org/10.2165/00128415-200711380-00063.

Texto completo
Los estilos APA, Harvard, Vancouver, ISO, etc.
31

&NA;. "Oxaliplatin." Reactions Weekly &NA;, no. 1140 (2007): 17. http://dx.doi.org/10.2165/00128415-200711400-00058.

Texto completo
Los estilos APA, Harvard, Vancouver, ISO, etc.
32

&NA;. "Oxaliplatin." Reactions Weekly &NA;, no. 1141 (2007): 17–18. http://dx.doi.org/10.2165/00128415-200711410-00061.

Texto completo
Los estilos APA, Harvard, Vancouver, ISO, etc.
33

&NA;. "Oxaliplatin." Reactions Weekly &NA;, no. 1149 (2007): 19–20. http://dx.doi.org/10.2165/00128415-200711490-00058.

Texto completo
Los estilos APA, Harvard, Vancouver, ISO, etc.
34

&NA;. "Oxaliplatin." Reactions Weekly &NA;, no. 1156 (2007): 20. http://dx.doi.org/10.2165/00128415-200711560-00062.

Texto completo
Los estilos APA, Harvard, Vancouver, ISO, etc.
35

&NA;. "Oxaliplatin." Reactions Weekly &NA;, no. 1160 (2007): 24–25. http://dx.doi.org/10.2165/00128415-200711600-00068.

Texto completo
Los estilos APA, Harvard, Vancouver, ISO, etc.
36

&NA;. "Oxaliplatin." Reactions Weekly &NA;, no. 1360 (2011): 29. http://dx.doi.org/10.2165/00128415-201113600-00099.

Texto completo
Los estilos APA, Harvard, Vancouver, ISO, etc.
37

&NA;. "Oxaliplatin." Reactions Weekly &NA;, no. 1361 (2011): 31–32. http://dx.doi.org/10.2165/00128415-201113610-00111.

Texto completo
Los estilos APA, Harvard, Vancouver, ISO, etc.
38

&NA;. "Oxaliplatin." Reactions Weekly &NA;, no. 1363 (2011): 31. http://dx.doi.org/10.2165/00128415-201113630-00122.

Texto completo
Los estilos APA, Harvard, Vancouver, ISO, etc.
39

&NA;. "Oxaliplatin." Reactions Weekly &NA;, no. 1366 (2011): 24. http://dx.doi.org/10.2165/00128415-201113660-00090.

Texto completo
Los estilos APA, Harvard, Vancouver, ISO, etc.
40

&NA;. "Oxaliplatin." Reactions Weekly &NA;, no. 1368 (2011): 31–32. http://dx.doi.org/10.2165/00128415-201113680-00115.

Texto completo
Los estilos APA, Harvard, Vancouver, ISO, etc.
41

&NA;. "Oxaliplatin." Reactions Weekly &NA;, no. 1368 (2011): 32. http://dx.doi.org/10.2165/00128415-201113680-00117.

Texto completo
Los estilos APA, Harvard, Vancouver, ISO, etc.
42

&NA;. "Oxaliplatin." Reactions Weekly &NA;, no. 1368 (2011): 32. http://dx.doi.org/10.2165/00128415-201113680-00119.

Texto completo
Los estilos APA, Harvard, Vancouver, ISO, etc.
43

&NA;. "Oxaliplatin." Reactions Weekly &NA;, no. 1370 (2011): 30. http://dx.doi.org/10.2165/00128415-201113700-00105.

Texto completo
Los estilos APA, Harvard, Vancouver, ISO, etc.
44

&NA;. "Oxaliplatin." Reactions Weekly &NA;, no. 1371 (2011): 29. http://dx.doi.org/10.2165/00128415-201113710-00109.

Texto completo
Los estilos APA, Harvard, Vancouver, ISO, etc.
45

&NA;. "Oxaliplatin." Reactions Weekly &NA;, no. 1374 (2011): 28. http://dx.doi.org/10.2165/00128415-201113740-00100.

Texto completo
Los estilos APA, Harvard, Vancouver, ISO, etc.
46

&NA;. "Oxaliplatin." Reactions Weekly &NA;, no. 1375 (2011): 24. http://dx.doi.org/10.2165/00128415-201113750-00080.

Texto completo
Los estilos APA, Harvard, Vancouver, ISO, etc.
47

&NA;. "Oxaliplatin." Reactions Weekly &NA;, no. 1375 (2011): 24. http://dx.doi.org/10.2165/00128415-201113750-00082.

Texto completo
Los estilos APA, Harvard, Vancouver, ISO, etc.
48

L??vi, Francis, Gerard Metzger, Claire Massari, and Gerard Milano. "Oxaliplatin." Clinical Pharmacokinetics 38, no. 1 (2000): 1–21. http://dx.doi.org/10.2165/00003088-200038010-00001.

Texto completo
Los estilos APA, Harvard, Vancouver, ISO, etc.
49

Carlson, Robert. "Oxaliplatin." Inpharma Weekly &NA;, no. 1130 (1998): 3–4. http://dx.doi.org/10.2165/00128413-199811300-00003.

Texto completo
Los estilos APA, Harvard, Vancouver, ISO, etc.
50

&NA;. "Oxaliplatin." Reactions Weekly &NA;, no. 772 (1999): 10. http://dx.doi.org/10.2165/00128415-199907720-00034.

Texto completo
Los estilos APA, Harvard, Vancouver, ISO, etc.
También puede estar interesado en las bibliografías sobre el tema "Oxaliplatin" para otros tipos de fuentes:
Tesis
Ofrecemos descuentos en todos los planes premium para autores cuyas obras están incluidas en selecciones literarias temáticas. ¡Contáctenos para obtener un código promocional único!

Pasar a la bibliografía